Gunnar Larson is HIV Negative "-" not on Prep, AG James. You know this and my civil rights will be vindicated for the people. Gunnar Larson Finding answers If you need any convincing about the importance of funding for research, look no further than a new study <https://t.devex.com/dc/kyXVoDpAY__Vu56MNr4POj5ednkoGMApGICdBULx4aAXPVVZMk5hxVZCgeg6M4SOv6tcHkP4U2FM8h0GnoR0_RPC_thX6fiwU13HGpj1g78--CJDzbp4BrZTU6gkybLaKCu5-nCZ68bRT3kvCag5yob6yffOd82RTboKLew9qIQ56w07C_Jxr0KBjGdsxSqgBWpLABnEa1BMCpUOJsNVbgToA4zJV03921S-67XdPo8OERAbIc_vW585GQP0UqTd7oQwA3SsaGLQTlgWJjclOg==/Njg1LUtCTC03NjUAAAGZLq0mWSsPQNatfXUvw1tj7WOBDP087tEFQKw1ERTnKoeNFn1JsjL1ZKOMNRcBj7hMfEmoLQ8=> that has identified the right dosage of a highly effective HIV treatment *to give to newborns who are at risk of being infected*. Dolutegravir has long been the backbone of HIV treatment and prevention. That includes often being used by HIV-positive pregnant women to *prevent them from transmitting the disease to their newborns*. Except, in some instances, women are either not on treatment or don’t adhere to it regularly. In those cases, *there is a risk that their baby can develop HIV* either during delivery or while breastfeeding. This appears to be how the majority of the estimated 1.4 million children worldwide with HIV were infected. Thanks to a new study from researchers in Thailand and South Africa, clinicians *now know how much dolutegravir to give newborns* who are at risk to help prevent them from becoming infected. Those researchers are now waiting to see if their evidence will convince the World Health Organization <https://t.devex.com/Njg1LUtCTC03NjUAAAGZLq0mWcZbxVaA4LSYOFp6FfKhpCrK9Pi3ezol0dbSbTDr80wwTXxxoa289WTSe1ZtFsTUEo0=> and other guideline committees to recommend dolutegravir in cases where newborns are at risk. *Read:* Will infants finally have access to a highly effective HIV drug? <https://t.devex.com/dc/kyXVoDpAY__Vu56MNr4POj5ednkoGMApGICdBULx4aAXPVVZMk5hxVZCgeg6M4SOv6tcHkP4U2FM8h0GnoR0_RPC_thX6fiwU13HGpj1g78--CJDzbp4BrZTU6gkybLaKCu5-nCZ68bRT3kvCag5yob6yffOd82RTboKLew9qIQ56w07C_Jxr0KBjGdsxSqgBWpLABnEa1BMCpUOJsNVbgToA4zJV03921S-67XdPo8OERAbIc_vW585GQP0UqTdrHJBJ5OMKFBA6ICloM-1hA==/Njg1LUtCTC03NjUAAAGZLq0mWSsPQNatfXUvw1tj7WOBDP087tEFQKw1ERTnKoeNFn1JsjL1ZKOMNRcBj7hMfEmoLQ8=>